Wuxi Biologics (Cayman), Inc. is a top player in the pharmaceutical industry based in China. With a strong ESG score of 10.7, the company is recognized for its low risk profile. Originally formed in 2014 as part of WuXi PharmaTech, now known as WuXi AppTec, the company boasts global revenue of CNY 17 billion, with a significant portion coming from North America. Wuxi Biologics follows a unique follow and win the molecule strategy, offering a wide range of services from drug discovery to commercial manufacturing. Additionally, the company utilizes a global dual-sourcing approach for producing drug products and large-scale drug substances.